Compare PHAR & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | PGY |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | PHAR | PGY |
|---|---|---|
| Price | $17.10 | $11.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.00 | $34.50 |
| AVG Volume (30 Days) | 32.4K | ★ 5.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.75 | $14.73 |
| Revenue Next Year | $9.39 | $14.27 |
| P/E Ratio | $3,041.22 | ★ $13.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $8.50 |
| 52 Week High | $21.34 | $44.99 |
| Indicator | PHAR | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 28.03 |
| Support Level | $16.35 | N/A |
| Resistance Level | $17.08 | $15.46 |
| Average True Range (ATR) | 0.57 | 0.99 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 77.74 | 11.77 |
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.